advertisement
Abstract #25594 Published in IGR 12-1
Longterm follow-up of diode laser transscleral cyclophotocoagulation in the treatment of refractory glaucoma
Frezzotti P; Mittica V; Martone G; Motolese I; Lomurno L; Peruzzi S; Motolese EActa Ophthalmologica 2010; 88: 150-155
Purpose: This prospective study was conducted to evaluate the efficacy and safety of transscleral diode laser cyclophotocoagulation (TDLCP) in advanced refractory glaucoma. Methods: A total of 124 eyes in 121 patients with advanced glaucoma refractory to medical treatment were treated consecutively with TDLCP. Success was defined as final intraocular pressure (IOP) of 5-21 mmHg in eyes with visual acuity (VA) of more than hand movements (HM) and relief of pain in eyes with VA of HM or less, including blind eyes. Results: Mean patient age was 65.6 (plus or minus) 17.1 years (range 14-91 years). Mean follow-up was 17 (plus or minus) 14.6 months (range 3-42 months). Mean pretreatment IOP was 29.9 (plus or minus) 8.4 mmHg (range 17-58 mmHg) and IOP at last follow-up was 20.8 (plus or minus) 8 mmHg (range 6-45 mmHg) (p < 0.001). The number of laser applications (mean 9.2 (plus or minus) 2.8, range 4-15) and maximal laser power (mean 2.01 (plus or minus) 0.22 mW, range 1.3-3.0 mW) were not associated with lower postoperative IOP. Intraocular pressure of (less-than or equal to) 21 mmHg was recorded in 63.0% of eyes at the last follow-up visit. Overall, 28 (21.7%) eyes required at least one retreatment. No phthisis bulbi or persistent hypotonia developed. Conclusions: TDLCP is an effective and safe method for the treatment of advanced refractory glaucoma, although repeated treatments are often necessary.
G. Martone. Gianluca Martone MD Department of Ophthalmology and Neurosurgery, University of Siena, Viale Bracci, 53100 Siena, Italy. gianlumart1@interfree.it
Classification:
12.10 Cyclodestruction (Part of: 12 Surgical treatment)
